|
Ronald A. Martell was appointed president and chief operating officer in May 2007. He joined the Board of Directors in June 2006. He recently served as senior vice president of Commercial Operations at ImClone Systems Incorporated and member of ImClone Systems� management committee. In that position he oversaw sales marketing and project and alliance management. He also guided corporate strategic and portfolio planning and management for the Company. He built ImClone Systems� Commercial Operations and field sales force to market and commercialize Erbitux� for the treatment of certain patients with colorectal and head and neck cancers with partners Bristol-Myers Squibb and Merck KGaA. Prior to joining ImClone Systems Mr. Martell worked for 10 years at Genentech in a variety of positions most recently as manager oncology products. At Genentech he was responsible for marketing Herceptin�for metastatic HER-2 positive breast cancer and Rituxan� for non-Hodgkin�s lymphoma. | 